Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806625 | 0.87 | HSP90AA1 (0.48) | HSP90AA1ENPP2HSP90AB1HSP90B1HPGD | |
| SCHEMBL803600 | 0.82 | MAPT (0.63) | HSP90AA1ENPP2MAPTPDGFRB | |
| SCHEMBL28884637 | 0.81 | MAPT (0.51) | HSP90AA1ENPP2HSP90AB1MAPTHSP90B1 | |
| SCHEMBL5776309 | 0.80 | HSP90AA1 (0.44) | HSP90AA1ENPP2HSP90AB1MAPTHSP90B1 | |
| SCHEMBL23501691 | 0.78 | HSP90AB1 (0.59) | HSP90AB1PDGFRB | |
| SCHEMBL31340129 | 0.78 | HSP90AA1 (0.47) | HSP90AA1ENPP2HSP90AB1MAPTHSP90B1 | |
| SCHEMBL28518471 | 0.78 | HSP90AA1 (0.47) | HSP90AA1ENPP2HSP90AB1MAPTHSP90B1 | |
| SCHEMBL786050 | 0.78 | KDR (0.45) | HSP90AA1ENPP2HSP90AB1MAPTHSP90B1 | |
| SCHEMBL21326642 | 0.78 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1MAPTHSP90B1PDGFRB | |
| SCHEMBL785054 | 0.77 | MAPT (0.43) | HSP90AA1ENPP2HSP90AB1MAPTHSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | HSP90AA1 2767/4885ENPP2 1718/4885HSP90AB1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.